Warning: The NCBI web site requires JavaScript to function. more...
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.
Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, Fetsch P, Filie A, Walters SA, Astry C, Aricó E, Zhao Y, Selleri S, Wang E, Marincola FM.
Genome Biol. 2007;8(1):R8.
Related citations
Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
Urosevic M, Oberholzer PA, Maier T, Hafner J, Laine E, Slade H, Benninghoff B, Burg G, Dummer R.
Clin Cancer Res. 2004 Aug 1;10(15):4959-70.
Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G, Gilliet M.
J Natl Cancer Inst. 2005 Aug 3;97(15):1143-53.
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, Garcia Diez A, Tebbs V, McRae S.
Br J Dermatol. 2005 May;152(5):939-47.
Gene expression profiling of cutaneous wound healing.
Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, Norwood C, Wang E, Marincola FM, Stroncek DF.
J Transl Med. 2007 Feb 21;5:11.
Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.
Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R.
Arch Dermatol. 2003 Oct;139(10):1325-32.
Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle.
Berman B, Sullivan T, De Araujo T, Nadji M.
Br J Dermatol. 2003 Nov;149 Suppl 66:59-61.
Imiquimod: in superficial basal cell carcinoma.
Oldfield V, Keating GM, Perry CM.
Am J Clin Dermatol. 2005;6(3):195-200; discussion 201-2. Review.
Imiquimod in basal cell carcinoma: how does it work?
Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G.
Br J Dermatol. 2003 Nov;149 Suppl 66:57-8.
Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
Torres A, Storey L, Anders M, Miller RL, Bulbulian BJ, Jin J, Raghavan S, Lee J, Slade HB, Birmachu W.
J Transl Med. 2007 Jan 26;5:7.
Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod.
Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, Schön MP.
J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49.
[New perspective in immunotherapy: local imiquimod treatment].
Kemény L, Nagy N.
Orv Hetil. 2010 May 9;151(19):774-83. Review. Hungarian.
Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod.
Wuest M, Dummer R, Urosevic M.
Arch Dermatol Res. 2007 Dec;299(10):493-8. Epub 2007 Oct 6.
In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma.
De Giorgi V, Salvini C, Chiarugi A, Paglierani M, Maio V, Nicoletti P, Santucci M, Carli P, Massi D.
Int J Dermatol. 2009 Mar;48(3):312-21.
Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping.
Sullivan TP, Dearaujo T, Vincek V, Berman B.
Dermatol Surg. 2003 Dec;29(12):1181-6.
Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma.
Sapijaszko MJ.
Skin Therapy Lett. 2005 Jul-Aug;10(6):2-5. Review.
Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK Jr, Carroll MT.
Cutis. 2007 Mar;79(3):241-8.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells.
Barnetson RS, Satchell A, Zhuang L, Slade HB, Halliday GM.
Clin Exp Dermatol. 2004 Nov;29(6):639-43.
Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J, Uerlich M, Haller O, Bieber T, Tueting T.
J Cutan Pathol. 2005 Apr;32(4):257-62.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on